Vincristine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Vincristine
- Pharmacist Assessment Report
- Vincristine: Vertebral anomalies and variable endocrine and T-cell dysfunction
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Vincristine: Vertebral anomalies and variable endocrine and T-cell dysfunction
One-Sentence Summary
Vincristine is a cytotoxic injectable anticancer drug. The TxGNN model predicts it may be useful for vertebral anomalies and variable endocrine and T-cell dysfunction, a rare syndromic disorder. The data compiled for this report contain 0 clinical trials and 0 publications for this disease, so the prediction is model-based only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Vertebral anomalies and variable endocrine and T-cell dysfunction |
| TxGNN Prediction Score | 0.9924 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (16 of 16) – CDSCO approval status is not included in this data |
| Number of Listed Products | 16 (valid: 16) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for vincristine are not available in the data compiled for this report. Vincristine is a vinca alkaloid, a class that binds tubulin and blocks microtubule formation. This arrests rapidly dividing cells in mitosis, which explains its use in blood cancers.
The predicted disease is a rare syndrome of vertebral malformation, endocrine abnormalities and T-cell dysfunction. Its core problem is developmental or immune, not uncontrolled cell proliferation. No therapeutic rationale for a cytotoxic, anti-mitotic drug can be established from the supplied data. The very high score from the TxGNN model (deep learning) (0.9924) is not backed by any trial or publication, and it may reflect similarities the model learned between related diseases, not biological evidence. Treat the prediction as a hypothesis only, not as a lead supported by biology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
The records contain no approved-indication text, so no approved use can be stated from them. Five examples:
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 237878 | Vcad 1mg Injection | Vial of 1 injection | Cadila Pharmaceuticals Ltd |
| 165312 | Oncocristin AQ 1mg Injection | Vial of 1 ml injection | Sun Pharmaceutical Industries Ltd |
| 234694 | Vincreta 1mg Injection | Vial of 1 injection | Metta Life Sciences Private Limited |
| 31216 | Biocristin AQ 1mg Injection | Vial of 1 ml injection | Biochem Pharmaceutical Industries |
| 36318 | Cytocristin 1mg Injection | Vial of 1 ml injection | Cipla Ltd |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (vinca alkaloid, anti-microtubule) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Blood counts (CBC with differential), liver function and neurological status. The knowledge graph links the drug to liver failure, cholestasis, leukopenia and peripheral neuropathy as contraindication relations |
| Handling Protection | Follow cytotoxic drug handling regulations |
Safety Considerations
- Contraindication relations in the knowledge graph (not label text): liver failure, cholestasis and other hyperbilirubinaemia conditions (including Gilbert syndrome), leukopenia, peripheral neuropathy and other neuromuscular diseases (including Charcot-Marie-Tooth disease), acute urate nephropathy, and fungal or other infectious disease.
- Drug interactions: 505 interactions are recorded. The one listed as major is clarithromycin. Moderate interactions include aprepitant, dexamethasone, metronidazole, miconazole, rolapitant, simvastatin, rosuvastatin, naltrexone, eliglustat, tinidazole, troglitazone and glycerol phenylbutyrate.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no trials or publications for this disease, and no plausible link between an anti-mitotic cytotoxic drug and a developmental or immune syndrome. Vincristine’s toxicity (nerve, liver and blood-count effects) is also hard to justify without any supporting evidence.
To proceed, the following is needed:
- An independent biological rationale, such as disease mechanism, or preclinical or case-level data for this syndrome
- Mechanism-of-action data for the drug
- Package insert warnings and contraindications for the India-licensed products
- A benefit-risk assessment for a rare, likely non-malignant condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.